Related Experiment Video
Updated: Jun 5, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Increase in CIP2A expression is associated with doxorubicin resistance
Yeon A Choi1, Jeong Su Park, Mi Young Park
1Research Center for Women's Disease, Department of Life Science, Sookmyung Women's University, Seoul 140-742, Republic of Korea.
FEBS Letters
|January 19, 2011
Summary
Cancerous inhibitor of protein phosphatase 2A (CIP2A) affects doxorubicin sensitivity in breast cancer cells. Mutant p53 and phosphorylated Akt influence CIP2A regulation by doxorubicin.
Area of Science:
- Molecular oncology
- Cancer cell biology
- Drug resistance mechanisms
Background:
- Cancerous inhibitor of protein phosphatase 2A (CIP2A) promotes cancer cell migration, metastasis, and proliferation.
- CIP2A overexpression is linked to increased proliferation in MDA-MB-231 breast cancer cells.
- The role of CIP2A in chemoresistance, particularly to doxorubicin, requires further investigation.
Purpose of the Study:
- To investigate the association between CIP2A expression and doxorubicin sensitivity in cancer cells.
- To elucidate the regulatory mechanisms of doxorubicin-mediated CIP2A expression.
- To explore the influence of p53 status on CIP2A regulation by doxorubicin.
Main Methods:
- Differential expression analysis of CIP2A in MDA-MB-231 and MCF-7 cells treated with doxorubicin.
- Overexpression studies of CIP2A in MCF-7 cells to assess its impact on doxorubicin response.
- Investigation of CIP2A expression in HCT116 cells with wild-type and mutant p53 following doxorubicin treatment.
- Analysis of phosphorylated Akt involvement in doxorubicin-mediated CIP2A regulation.
Main Results:
- Doxorubicin treatment increased CIP2A expression in MDA-MB-231 cells but decreased it in MCF-7 cells.
- Overexpression of CIP2A in MCF-7 cells conferred resistance to doxorubicin-induced proliferation inhibition.
- Mutant p53, but not wild-type p53, inhibited doxorubicin-mediated down-regulation of CIP2A in HCT116 cells.
- Phosphorylated Akt was identified as a key factor in suppressing CIP2A expression during doxorubicin treatment.
Conclusions:
- CIP2A expression levels are differentially regulated by doxorubicin in distinct breast cancer cell lines.
- CIP2A plays a significant role in mediating resistance to doxorubicin, suggesting it as a potential therapeutic target.
- Mutant p53 and the Akt signaling pathway are critical regulators of CIP2A response to doxorubicin therapy.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...